Efficacy of hydrogen peroxide wipes for decontamination of AZD1222 adenovirus COVID-19 vaccine strain on pharmaceutical industry materials

V.P. Rhodes, A.C.F.B. Ajobio, L.V. da Costa, A.P. Rodrigues, V.A. Diniz, R.V. da Silva Lage, I.B. da Silva and M.L.L. Brandão

Laboratory of Microbiology Control, Department of Quality Control, Bio-Manguinhos/Fiocruz, Rio de Janeiro, Brazil

Significance and Impact of Study: The disinfection procedure with hydrogen peroxide® wipes (HPW) resulted in complete decontamination of AZD1222 chimpanzee adenovirus strain in formulated recombinant COVID-19 vaccine (≥7.46 and ≥7.49 log_{10} infectious unit [IFU] ml^{-1} for stainless steel [SS] and low-density-polyethylene [LDP] carriers respectively) and active pharmaceutical ingredient (≥8.79 and ≥8.78 log_{10} IFU ml^{-1} for SS and LDP carriers respectively). HPW can be a good option for disinfection processes in pharmaceutical industry facilities during recombinant COVID-19 vaccine production. This procedure is simple and can be also applied on safety unit cabins and sampling bags made of LDP as well.

Keywords
biopharmaceuticals, pharmaceuticals, quality control, vaccines, viruses.

Correspondence
Marcelo Luiz Lima Brandão, Laboratory of Microbiology Control, Department of Quality Control, Bio-Manguinhos/Fiocruz, Av. Brasil, 4365, Manguinhos, Rio de Janeiro, RJ CEP-21040-900, Brazil.
E-mail: marcelo.brandao@bio.fiocruz.br

2022/LAMICRO-2022-0450.R1: received 2 August 2022, revised 30 August 2022 and accepted 2 September 2022
doi:10.1111/lam.13831

Abstract
This study aimed to evaluate the performance of accelerated hydrogen peroxide® wipes (HPW) for decontamination of the chimpanzee adenovirus AZD1222 vaccine strain used in the production of recombinant COVID-19 vaccine in a pharmaceutical industry. Two matrices were tested on stainless-steel (SS) and low-density-polyethylene (LDP) surfaces: formulated recombinant COVID-19 vaccine (FCV) and active pharmaceutical ingredient (API). The samples were spiked, dried and the initial inoculum, possible residue effect (RE) and titre reduction after disinfection with HPW were determined. No RE was observed. The disinfection procedure with HPW resulted in complete decontamination the of AZD1222 adenovirus strain in FCV (≥7.46 and ≥7.49 log_{10} infectious unit [IFU] ml^{-1} for SS and LDP carriers respectively) and API (≥8.79 and ≥8.78 log_{10} IFU ml^{-1} for SS and LDP carriers respectively). In conclusion, virucidal activity of HPW was satisfactory against the AZD1222 adenovirus strain and can be a good option for disinfection processes of SS and LDP surfaces in pharmaceutical industry facilities during recombinant COVID-19 vaccine production. This procedure is simple and can be also applied on safety unit cabins and sampling bags made of LDP as well.

Introduction
The Brazilian National Immunization Program (NIP) coordinates vaccination at national level and offers vaccines established at the National Vaccination Calendar, which is one of the most extensive in the world (Matos et al. 2020). The Immunobiological Technology Institute/Oswaldo Cruz Foundation (Bio-Manguinhos/Fiocruz) produces vaccines to supply the NIP. Due to the pandemic, the large-scale production of the recombinant COVID-19 vaccine (VCD) was necessary to achieve the immunization of the population (Matos et al. 2020). The ChAdOx1-S/nCoV-19 recombinant vaccine is a replication-deficient adenoviral vector vaccine that expresses the SARS-CoV-2 spike protein gene (WHO 2021).

During sterile biologicals production, cleaning validation plays an important role in reducing the possibility of product contamination from manufacturing equipment. The cleaning process must be validated to guarantee that
residues of infectious materials have been removed from the equipment, so they can be used for several products manufacturing (PDA 2012).

Hydrogen peroxide is an environmentally safe chemical residue free disinfectant that has been used for environmental decontamination in various types of industries, including pharmaceutical, generally using vapour equipment (Gradini et al. 2019; Vannier and Chewins 2019; Kindermann et al. 2020; Ajorio et al. 2021, 2022). Other types of application include the use of soaked hydrogen peroxide wipes (HPW), which seems an attractive choice for different types of surfaces as part of a preventive risk mitigation concept (Rosenberg et al. 2011; Kindermann et al. 2020).

Previous studies that evaluated the efficacy of HPW to eliminate pathogenic human viruses from clinical interesting surfaces (e.g. tonometer tips) using disc-based carrier assays presented promising results (Threlkeld et al. 1993; Gradini et al. 2019; Cutts et al. 2020, 2021; Malenovská 2020). However, HPW have not been used yet to investigate the virucidal efficacy in surfaces of equipment and facilities in pharmaceutical industries.

The aim of this study was to evaluate the performance of HPW to decontaminate the AZD1222 chimpanzee adenovirus vaccine strain, used in the production of VCD in different matrices and surfaces for application in facilities cleaning validation.

Results and discussion

The results of the samples and reference material (RM) titrations are presented in Table 1. The carrier’s disinfection procedure was satisfactory and no visible growth of bacteria was observed in brain–heart infusion broth (BHI) after incubation. No infectious unit (IFU) was observed in the negative controls and the RM presented satisfactory results according to the established criteria. The formulated recombinant COVID-19 vaccine (FCV) and active pharmaceutical ingredient (API) used for spiking, after 1 h in room temperature (20–25°C), contained 7.88 and 9.18 log10 IFU ml⁻¹ respectively (Table 1).

After the inoculation and drying, no titre loss was observed for both matrices and surfaces (Table 2). According to standard NF-T-72-281:2014 (L’Association Francaise de Normalisation 2014) difference between inoculum control and residue effect (RE) must be <0.5 log10 IFU ml⁻¹. In the present study, the differences observed were ≤0.04 log10, indicating absence of RE in the test. In disinfected carriers, no IFU was observed in any inoculated dilution, and the calculated titre was ≤0.42 log10 IFU ml⁻¹. Therefore, the disinfection procedure resulted in complete decontamination of AZD1222 chimpanzee adenovirus strain present in FCV (≥7.46 and ≥7.49 log10 IFU ml⁻¹ for stainless-steel [SS] and low-density-polyethylene [LDP] carriers respectively) and API (≥8.79 and ≥8.78 log10 IFU ml⁻¹ for SS and LDP carriers respectively).

Sattar and Maillard (2013) used the term decontamination to encompass both the physical removal and the inactivation functions of such wipes. In the present study, the ready-to-use commercial HPW showed satisfactory results for decontamination (removal and inactivation) of AZD1222 chimpanzee adenovirus strain in both matrices and surfaces evaluated. However, as wipes without hydrogen peroxide were not included as controls, the contribution of the hydrogen peroxide and the mechanical intervention cannot be measured individually.

Hydrogen peroxide acts against viruses by forming HO free radicals which react with thiol groups in proteins and

| Table 1 | Titre of AZD1222 chimpanzee adenovirus vaccine strain present in the FCV, API and RM |
| Sample | Series | Titre (IFU ml⁻¹) | Average titre (IFU ml⁻¹) | CV (%) | Log10 average titre (IFU ml⁻¹) |
|---|---|---|---|---|---|
| FCV | 1 | 1·35 × 10⁹ | 1·51 × 10⁹ | 14·3 | 7·88 |
| | 2 | 1·66 × 10⁹ | 1·72 × 10⁹ | 11·0 | 8·21 |
| API | 1 | 2·88 × 10¹⁰ | 3·00 × 10¹⁰ | 5·7 | 9·18 |
| | 2 | 3·12 × 10¹⁰ | 3·20 × 10¹⁰ | 5·2 | 9·24 |
| RM | 1 | 1·68 × 10⁹ | 1·68 × 10⁹ | 0 | 9·23 |
| | 2 | 1·68 × 10⁹ | 1·68 × 10⁹ | 0 | 9·23 |

API: active pharmaceutical ingredient of COVID-19 vaccine; CV: coefficient of variation; FCV, formulated COVID-19 vaccine; IFU: infectious units; RM, reference material.

| Table 2 | Virucidal efficacy of peroxide wipes against AZD1222 chimpanzee adenovirus vaccine strain present in formulated COVID-19 (recombinant) vaccine and active pharmaceutical ingredient of COVID-19 (recombinant) vaccine dried in stainless-steel (SS) and low-density-polyethylene (LDP) surfaces |
| Sample | Surface | Carrier | Average titre (IFU ml⁻¹) | Log10 average titre (IFU ml⁻¹) |
|---|---|---|---|---|
| FCV | SS | IC | 7·60 × 10⁷ | 7·88 |
| | RE | 6·97 × 10⁷ | 7·84 |
| | DC ≤2·63 × 10⁰ | ≤0·42 |
| | LDP | IC | 8·15 × 10⁷ | 7·91 |
| | RE | 8·02 × 10⁷ | 7·90 |
| | DC ≤2·63 × 10⁰ | ≤0·42 |
| API | SS | IC | 1·62 × 10⁹ | 9·21 |
| | RE | 1·65 × 10⁹ | 9·22 |
| | DC ≤2·63 × 10⁰ | ≤0·42 |
| | LDP | IC | 1·60 × 10⁹ | 9·20 |
| | RE | 1·60 × 10⁹ | 9·20 |
| | DC ≤2·63 × 10⁰ | ≤0·42 |

API: active pharmaceutical ingredient of COVID-19 vaccine; DC: disinfectant carrier; FCV, formulated COVID-19 vaccine; IC: inoculum control; IFU, infectious units; RE: residue effect; SS, stainless steel surface; LDP, low-density-polyethylene surface.
nucleic acids, thus inhibiting the infection replication process (Finnegan et al. 2010). Previous studies reported problems with hydrogen peroxide residue (death of cell monolayer in titrating assay) during the evaluation of liquid (1–30%) and HPV virucidal activity (Ajorio et al. 2021, 2022). According to the manufacturer, the concentration of accelerated hydrogen peroxide in Oxivir TB Wipes (OTW) is 0.50–0.55%, which is lower than the used in others studies (Ajorio et al. 2021, 2022) and can explain why no RE was observed in the present study.

According to NF T72-281:2014 (L’Association Francaise de Normalisation 2014), a 4 log10 reduction is recommended for virus decontamination and HPW was sufficient to reach this target (≥7–46 log10) for all matrices and surfaces evaluated. The OTW leaflet describes that the product has virucidal activity against Influenza virus H1N1. These results were similar to those of other authors that evaluated the virucidal efficacy of HPW against adenovirus strains and reported complete decontamination (>4.83 to >8 log10) (Berrie et al. 2011; Cutts et al. 2021). Cutts et al. (2020) observed a reduction of −5.5 log10 after 5 s and −6.4 log10 after 60 s of Ebola virus Makona variant, and complete decontamination (~6.2 log10) after 5 s of vesicular stomatitis virus in impregnated 4 × 4 cm wipes with 1:40 solution of accelerated hydrogen peroxide. When applied in SS surfaces, decontamination of ~6 log10 was observed for both viruses. In plastic surfaces, such as Goldmann tonometers and pneumotachometer tips, similar results were reported (Threlkeld et al. 1993; Malenovská 2020). Threlkeld et al. (1993) evaluated the efficacy of 3% HPW over adenovirus 8 and observed no virus recovery with an initial inoculum varying from 1.9 to 3.5 log10. Malenovská (2020) used Alpha-coronavirus 1 as a surrogate virus to investigate the persistence of coronavirus dried on a plastic carrier. Using wipes saturated with a combination of disinfectant agents, that included 0.5% hydrogen peroxide and 5 min of contact, complete decontamination was achieved (≥3.5 log10).

In conclusion, HPW showed efficacy for AZD1222 chimpanzee adenovirus vaccine strain decontamination in FCV and API matrices, being a promising disinfectant method for surfaces of SS and LPD in production areas and equipment. This procedure is simple and can be applied on safety unit cabins and sampling bags made of LDP as well.

Materials and methods

Virus samples, RM and chimpanzee adenovirus AZD1222 titration

The chimpanzee adenovirus AZD1222 vaccine strain was used for spiking experiments. The vaccine strain was tested in two presentations: (1) FCV and (2) API of VCD. One batch of VCD (lot: MRVCD01/21) was used as RM to validate the assays. Lower and higher confidence limits were previously established in a control chart: confidence limits = 9.23–9.32 log10 IFU ml⁻¹. Phosphate-buffered saline (PBS) pH 7.2 (Sigma-Aldrich, Saint Louis, MO) was used as negative control.

The titres of FCV, API, RM and samples were determined using the IFU methodology described by Ajorio et al. (2022). Two independent aliquots of undiluted and serial 10-fold dilutions of the samples were prepared in Dulbecco’s Modified Eagle Medium (DMEM) (Life Technologies, New York, NY) supplemented with 1% of penicillin–streptomycin (Life Technologies) and 10% of heat-inactivated foetal bovine serum (Life Technologies). Afterwards, inoculation of 0·1 ml into poly-D-lysine-coated 24-well plates containing 0·9 ml of HEK-293 (ATCC® CRL-1573TM) (2·8 × 10⁵ cells/ml) and incubated at 37°C with 5% CO₂ and ≥85% relative humidity for 47 h was realized. Two non-inoculated wells were used as controls in each microplate. After incubation, the cells were fixed with methanol (J.T. Baker, Chaganas, Republic of Trinidad and Tobago) and then washed with PBS pH 7.2 (Sigma-Aldrich). Afterwards, mouse anti-adenovirus (Abcam, Waltham, MA) was added in each well. After 60 min, the liquid was removed and the plates were washed with PBS. Then, rabbit anti-mouse IgG-HRP antibodies (Abcam) were added in each well. After 60 min, the liquid was removed and the plates were washed with PBS. Then, 1× DAB substrate kit (Thermo Fisher, Rockford, IL) was added in each well. After 10 min, the liquid was removed and the plates were washed with UltraPure DNase/RNase free water (Thermo Fisher). After, 1·0 ml of UltraPure water was added in each well and cell counting was realized using an inverted light microscope (Zeiss, Göttingen, Germany) with a 10× ocular lens with 20 mm of field diameter and a 10× objective lens. The infectious titre in log10 IFU ml⁻¹ was calculated using the following equation:

$$\text{Titre (log}_{10}\text{ IFU ml}^{-1}) = (\text{Average stained cell counts } \times \text{ number of fields } \times \text{ dilution factor})/\text{sample volume}$$

where the number of fields into an ocular lens with 20 mm of field diameter and 10× objective lens = 61, and the sample volume = 0·1 ml.

When no IFU was found in any dilution, the assay detection limit was calculated considering 1 IFU in the total volume of the lowest dilution inoculated.

Carriers’ preparation

Two different surface carriers were tested: SS and LPD. They were disinfected according to standard NF-T-72-281:2014 (L’Association Francaise de Normalisation 2014).
To verify the efficacy of disinfection and sterilization procedure, two carries of each type were added to tubes containing 20 ml of BHI (Merck, Darmstadt, Germany) and incubated at 32.5°C for 14 days.

**Spiking experiments: RE and HPW virucidal activity evaluation**

Two matrices were tested: FCV and API in SS and LDP surface carriers, based on the methodology described on standard NF-T-72-281:2014 (L’Association Francaise de Normalisation 2014). Five carriers of each type were placed in one Petri dish and spiked with 50 μl of PBS. After 1 h, the spiking inoculums were completely dried and the carriers were disinfected with OTW (Diversey, Ontario, Canada) with circling friction movements with pressure for 5 min, as recommended by the manufacturing instructions. Then, each carrier was added to tubes containing 10 ml of supplemented DMEM medium. The tubes were vortexed for 30 s and the contents were transferred to one flask (pool). This pool (~50 ml) containing the OTW residue was aliquoted into four new tubes (10 ml/tube) and further used for the RE evaluation (item 2.4.2). A schematic diagram of residue preparation is shown in Fig. 1.

In a biological safety cabinet, six Petri dishes were opened, and four carriers (two SS and two PBD) were placed into each dish. The carriers of three plates were spiked with 50 μl of FCV and the inoculum were spread with a bacteriological loop (Cralplast, São Paulo, Brazil). The same was made in API samples. After 1 h, the spiking inoculum were completely dried and the carriers of one plate of each matrix were added to tubes containing 10 ml of supplemented DMEM, used for the initial inoculum determination. The carriers of a second plate of each matrix were added to tubes containing 10 ml SS or LDP OTW residue (Fig. 1) for the RE evaluation. The carriers of the remaining plates were submitted to disinfection with OTW with circling friction movements with pressure for 5 min, as recommended by the manufacturing instructions (disinfected carrier). Then, they were added to tubes containing 10 ml of supplemented DMEM. All tubes were vortexed for 30 s and submitted to titration as previously described. A schematic diagram of sample spiking is shown in Fig. 2.

The FCV and API flasks used for spiking were kept inside the biological safety cabinet under the same conditions and two aliquots of each were taken and titrated. One vial of RM was analysed to validate the assay.

The log_{10} IFU ml\(^{-1}\) percent of reduction was calculated by comparing the titre of the undisinfected with the disinfected samples, using the following equation:

\[
\% \text{titre reduction (IFU ml}^{-1} \text{)} = 100 - \frac{\text{average of undisinfected samples} \times 100}{\text{average of disinfected samples}}.
\]

**Author contributions**

Vinicius Pessanha Rhodes: the conception and design of the study, acquisition of data, analysis and interpretation of data, drafting the article, final approval of the version to be submitted. Ana Carolina Ferreira Ballestê Ajorio: the conception and design of the study, acquisition of data, analysis and interpretation of data, drafting the article, final approval of the version to be submitted.
Luciana Veloso da Costa: the conception and design of the study, acquisition of data, analysis and interpretation of data, revising it critically for important intellectual content, final approval of the version to be submitted. Anderson Peclat Rodrigues: the conception and design of the study, acquisition of data, analysis and interpretation of data, drafting the article, final approval of the version to be submitted. Vanessa Alvaro Diniz: the conception and design of the study, acquisition of data, analysis and interpretation of data, drafting the article, final approval of the version to be submitted. Rebeca Vitória da Silva Lage: the conception and design of the study, acquisition of data, analysis and interpretation of data, drafting the article, final approval of the version to be submitted. Igor Barbosa da Silva: the conception and design of the study, acquisition of data, analysis and interpretation of data, revising it critically for important intellectual content, final approval of the version to be submitted.

Conflict of Interest

No conflict of interest declared.

Data availability statement

The data that supports the findings of this study are available in this article.

References

Ajorio, A.C.F.B., Rhodes, V.P., Rodrigues, A.P., Diniz, V.A., Mattoso, J.M.V., da Silva, I.B., Aiuto, D.M.M.D. and Brandão, M.L.L. (2022) Evaluation of hydrogen peroxide efficacy against AZD1222 chimpanzee adenovirus strain in the recombinant COVID-19 vaccine for application in cleaning validation in a pharmaceutical manufacturing industry. Lett Appl Microbiol 74, 536–542.

Ajorio, A.C.F.B., Rhodes, V.P., Rodrigues, A.P., Moreira, F.M., Diniz, V.A., Mattoso, J.M.V., da Silva, I.B., Guedes Junior, D.S. et al. (2021) Evaluation of hydrogen peroxide virucidal efficacy against yellow fever virus 17DD vaccine.
strain for application in a vaccine manufacturing industry. *J Pharm Biomed Anal* **204**, 114264.

Berrie, E., Andrews, L., Yezli, S. and Otter, J.A. (2011) Hydrogen peroxide vapour (HPV) inactivation of adenovirus. *Lett Appl Microbiol* **52**, 555–558.

Cutts, T.A., Kasloff, S.B., Krishnan, J., Nims, R.W., Theriault, S.S., Rubino, J.R. and Ijaz, M.K. (2021) Comparison of the efficacy of disinfectant pre-impregnated wipes for decontaminating stainless steel carriers experimentally inoculated with Ebola virus and vesicular stomatitis virus. *Front Public Health* **9**, 657443.

Cutts, T.A., Robertson, C., Theriault, S.S., Nims, R.W., Kasloff, S.B., Rubino, J.R. and Ijaz, M.K. (2020) Assessing the contributions of inactivation, removal, and transfer of Ebola virus and vesicular stomatitis virus by disinfectant pre-soaked wipes. *Front Public Health* **8**, 183.

Finnegan, M., Linley, E., Denyer, S.P., McDonnell, G., Simons, C. and Maillard, J.Y. (2010) Mode of action of hydrogen peroxide and other oxidizing agents: differences between liquid and gas forms. *J Antimicrob Chemother* **65**, 2108–2115.

Gradini, R., Chen, F., Tan, R. and Newlin, L. (2019) A summary on cutting edge advancements in sterilization and cleaning technologies in medical, food, and drug industries, and its applicability to spacecraft hardware. *Life Sci Space Res (Amst)* **23**, 31–49.

Kindermann, J., Karbiener, M., Leydold, S.M., Knotzer, S., Modrof, J. and Krell, T.R. (2020) Virus disinfection for biotechnology applications: different effectiveness on surface versus in suspension. *Biologicals* **64**, 1–9.

L’Association Francaise de Normalisation. (2014) NF T 72–281. *Procedes de disinfection des surfaces par voie aerienne determmination de l’activite bactericide, fungicide, levuricide, mycobactericide, tuberculocide, sporicide et virucide incluant les bacteriophages*. Paris: AFNOR.

Malenovská, H. (2020) Coronavirus persistence on a plastic carrier under refrigeration conditions and its reduction using wet wiping technique, with respect to food safety. *Food Environ Virol* **12**, 361–366.

Matos, C.C.S.A., Barbieri, C.L.A. and Couto, M.T. (2020) Covid-19 and its impact on immunization programs: reflections from Brazil. *Rev Saude Publica* **54**, 114.

Parenteral Drug Association – PDA. (2012) *Technical Report no. 29: Points to Consider for Cleaning Validation*. PDA Parental Drug Association ISBN: 978-0-939459-48-3.

Rosenberg, A.S., Cherney, B., Brorson, K., Clouse, K., Kozlowski, S., Hughes, P. and Friedman, R. (2011) Risk mitigation strategies for viral contamination of biotechnology products: consideration of best practices. *PDA J Pharm Sci Technol* **65**, 563–567.

Sattar, S. and Maillard, J. (2013) The crucial role of wiping in decontamination of high touch environmental surfaces: review of current status and directions for the future. *Am J Infect Control* **41**, S97–S104.

Threlkeld, A.B., Froggatt, J.W., 3rd, Schein, O.D. and Forman, M.S. (1993) Efficacy of a disinfectant wipe method for the removal of adenovirus 8 from tonometer tips. *Ophthalmology* **100**, 1841–1845.

Vannier, M. and Chewins, J. (2019) Hydrogen peroxide vapour is an effective replacement for formaldehyde in a BSL4 foot and mouth disease vaccine manufacturing facility. *Lett Appl Microbiol* **69**, 237–245.

World Health Organization – WHO. (2021) *COVID-19 Vaccine Explainer. COVID-19 Vaccine ChAdOx1-S [recombinant]*. Developed by Oxford University and AstraZeneca. 2021. https://www.who.int/publications/m/item/chadox1-s-recombinant-covid-19-vaccine (accessed 7 July 2022).